Atossa Therapeutics Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Advances ATNM Q1 2026 Earnings NarrowerthanExpected Loss Highlights Continued Clinical Progress SVRA Q1 2026 Earnings Wider Loss Amid Continued Pipeline Development GRRR Q4 2025 Earnings Significant EPS Miss but Stock Rises Over 12 Core Laboratories Q1 2026 Earnings EPS Misses Estimates as Market Challenges Persist Lockheed Martin Q1 2026 Earnings EPS Misses Estimates as Defense Backlog Supports Stock